120 results
Page 4 of 6
6-K
EX-99.1
iofuln5
5 Mar 21
ObsEva Announces Year End 2020 Financial Results
7:21am
6-K
EX-99.1
04coee4mr52 gnf8j4tg
10 Feb 21
ObsEva Provides Business Outlook for 2021
6:10am
6-K
EX-99.1
1efr5w9v2ba5
11 Jan 21
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
7:05am
6-K
EX-99.1
2caub24dyki6pjqrc
4 Jan 21
ObsEva appoints David Renas as Chief Financial Officer
6:36am
6-K
EX-99.1
he92sawebee0
10 Dec 20
Current report (foreign)
6:03am
6-K
EX-99.1
2kekn
24 Nov 20
Current report (foreign)
6:03am
6-K
EX-99.1
zegn 6knhgbeqbk
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
6-K
EX-99.1
ljvq3fqfoj ur9s
9 Nov 20
ObsEva appoints Brian O’Callaghan as Chief Executive Officer
7:32am
6-K
EX-1.1
9efyq
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
6-K
rn9zo7b buk6katy
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
6-K
EX-99.1
fhd3ll
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
6-K
EX-99.3
3a8bdyx69da
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.1
7kf8x l6b
6 Jul 20
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
6:18am
6-K
EX-99.1
0t3ge2i3hmad n9
1 Jul 20
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
6:15am
6-K
EX-99.1
rhw ppmrocgdwxpvyg5y
4 Jun 20
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
6:11am
6-K
EX-99.3
4si7ych45qa868pf
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.1
bmi8phct4r8h9p
23 Mar 20
ObsEva Provides Update Related to COVID-19 Pandemic
4:00pm